B&K (HKSE:02396) Shares Outstanding (Basic Average): 101.77 Mil (As of Dec. 2025)


HKSE:02396 B&K Corp Ltd HKSE:02396
8 GF Score
Price HK$4.18
! 1 Warning Sign
View Full Analysis

What is B&K Shares Outstanding (Basic Average)?

B&K HKSE:02396 -7.11% 8 Shares Outstanding (Basic Average) is 101.77 Mil as of Dec. 2025. GuruFocus rates HKSE:02396 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. B&K's average basic shares outstanding for the quarter that ended in Dec. 2025 was 101.77 Mil.

B&K  (HKSE:02396) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

B&K Shares Outstanding (Basic Average) Related Terms

B&K Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for B&K's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

B&K Shares Outstanding (Basic Average) Chart

B&K Annual Data
Trend Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
100.01 100.01 100.45

B&K Quarterly Data
Dec23 Dec24 May25 Sep25 Dec25
Shares Outstanding (Basic Average) 100.01 100.01 0.00 100.01 101.77
HKSE:02396
8GF Score
B&K Corp Ltd HKSE:02396
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

B&K Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 101.77 Mil mean?
B&K (HKSE:02396) has a Shares Outstanding (Basic Average) of 101.77 Mil as of Dec. 2025. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on B&K and its competitors.
Is B&K's Shares Outstanding (Basic Average) too high?
B&K's current Shares Outstanding (Basic Average) is 101.77 Mil. Overall, B&K has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does B&K's Shares Outstanding (Basic Average) compare to VRTX and REGN?
B&K's Shares Outstanding (Basic Average) of 101.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on B&K and its competitors. B&K's current Shares Outstanding (Basic Average) is 101.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is B&K stock overvalued right now?
B&K (HKSE:02396) has a current Shares Outstanding (Basic Average) of 101.77 Mil. The current Shares Outstanding (Basic Average) is 101.77 Mil. B&K's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For B&K (HKSE:02396), the current Shares Outstanding (Basic Average) is 101.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

B&K Business Description

Address No. 19 Qinling Road, Xiexin Center, Room 1507, Building 1, Laoshan District, Shandong Province, Qingdao, CHN
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score

Get the complete analysis for HKSE:02396

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.18
Price